Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Added thyroid gland undifferentiated (anaplastic) carcinoma and small cell lung carcinoma to the study's listed conditions.
    Difference
    0.1%
    Check dated 2026-03-27T23:28:57.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    - Revision: v3.5.0 updated from v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-20T19:55:54.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    Footer revision updated from v3.4.2 to v3.4.3. The change is cosmetic and does not alter content or functionality of the page.
    Difference
    0.0%
    Check dated 2026-03-06T18:00:12.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Difference
    0.1%
    Check dated 2026-02-13T12:22:07.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    Revision: v3.4.1 was added. Revision: v3.4.0 was removed.
    Difference
    0.0%
    Check dated 2026-02-05T23:44:53.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added and v3.3.3 was removed from the study documents.
    Difference
    0.0%
    Check dated 2026-01-15T04:29:00.000Z thumbnail image

Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.